Publication | Closed Access
Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma
36
Citations
14
References
2014
Year
Sorafenib may be effective and well tolerated, even in patients with advanced HCC who are aged 80 years and older, as well as those aged less than 80 years.
| Year | Citations | |
|---|---|---|
Page 1
Page 1